Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong
· Delayed Price · Currency is HKD 8.13
+0.12 (1.50%)
At close: Mar 10, 2026
HKG:2566 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | 123.43 | 138.6 | 119.78 | 59.87 | 119.41 |
| Depreciation & Amortization | 40.49 | 36.22 | 35.82 | 35.77 | 24.24 |
| Other Amortization | 0.72 | 0.72 | 0.32 | - | - |
| Loss (Gain) From Sale of Assets | 0.17 | 0.27 | 0.41 | 0.04 | 0.33 |
| Loss (Gain) From Sale of Investments | 12.36 | 6.5 | 1.22 | 0.46 | -0.08 |
| Stock-Based Compensation | 5.08 | 5.3 | 11.93 | 0.18 | 0.15 |
| Other Operating Activities | -5.1 | 26.24 | 26.62 | 12.74 | 7.24 |
| Change in Accounts Receivable | -115.15 | -144.3 | -62.47 | -82.03 | -131.24 |
| Change in Inventory | 2.87 | 11.39 | 0.91 | 27.79 | 49.16 |
| Change in Accounts Payable | 3.82 | -15.42 | -9.22 | -14.8 | -32.69 |
| Change in Unearned Revenue | -0.4 | 7.59 | -2.15 | -5.03 | 1.19 |
| Change in Other Net Operating Assets | 51.56 | 21.68 | 12.61 | -12.41 | 29.83 |
| Operating Cash Flow | 119.84 | 94.79 | 135.77 | 22.56 | 67.53 |
| Operating Cash Flow Growth | -12.22% | -30.19% | 501.82% | -66.59% | - |
| Capital Expenditures | -17.3 | -15.09 | -21.1 | -23.3 | -53.94 |
| Sale of Property, Plant & Equipment | 0.09 | 0.12 | 0 | 0.01 | 0.05 |
| Sale (Purchase) of Intangibles | -75.94 | -64.76 | -25.88 | -35.66 | -8.97 |
| Investing Cash Flow | -393.15 | -79.73 | -46.98 | -58.94 | -62.86 |
| Long-Term Debt Issued | - | 130.2 | 143.31 | 204.17 | 209.62 |
| Long-Term Debt Repaid | - | -176.55 | -196.16 | -170.3 | -158.65 |
| Net Debt Issued (Repaid) | -70.93 | -46.35 | -52.86 | 33.88 | 50.97 |
| Issuance of Common Stock | 521 | 521 | - | - | - |
| Common Dividends Paid | -1.56 | - | - | -12 | - |
| Other Financing Activities | -38.86 | -46.34 | -14.49 | -8.98 | -9.75 |
| Financing Cash Flow | 409.65 | 428.32 | -67.35 | 12.89 | 41.23 |
| Foreign Exchange Rate Adjustments | 2.46 | 1.08 | 0.21 | 0.2 | -0.12 |
| Net Cash Flow | 138.8 | 444.45 | 21.64 | -23.29 | 45.78 |
| Free Cash Flow | 102.54 | 79.69 | 114.66 | -0.74 | 13.59 |
| Free Cash Flow Growth | -12.12% | -30.50% | - | - | - |
| Free Cash Flow Margin | 7.85% | 5.82% | 8.91% | -0.07% | 1.04% |
| Free Cash Flow Per Share | 0.45 | 0.39 | 0.57 | -0.00 | 0.07 |
| Cash Interest Paid | 5.96 | 7.15 | 9.41 | 8.98 | 9.75 |
| Cash Income Tax Paid | 32.14 | 19.16 | -1.1 | -10.5 | 11.74 |
| Levered Free Cash Flow | 27.34 | 14.91 | 12.11 | -51.21 | - |
| Unlevered Free Cash Flow | 31.11 | 19.37 | 17.98 | -45.56 | - |
| Change in Working Capital | -57.31 | -119.06 | -60.32 | -86.5 | -83.76 |
Source: S&P Capital IQ. Standard template. Financial Sources.